Neuronetics, Inc. (NASDAQ:STIM) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC lessened its holdings in Neuronetics, Inc. (NASDAQ:STIM - Free Report) by 72.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,600 shares of the company's stock after selling 423,200 shares during the quarter. Renaissance Technologies LLC owned about 0.52% of Neuronetics worth $255,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of STIM. Geode Capital Management LLC grew its holdings in Neuronetics by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 314,076 shares of the company's stock worth $506,000 after acquiring an additional 8,466 shares during the period. JPMorgan Chase & Co. boosted its position in Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company's stock worth $88,000 after purchasing an additional 54,442 shares in the last quarter. David J Yvars Group grew its stake in shares of Neuronetics by 47.1% during the 4th quarter. David J Yvars Group now owns 46,325 shares of the company's stock worth $75,000 after purchasing an additional 14,825 shares during the period. Finally, Tradewinds LLC. acquired a new stake in shares of Neuronetics during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 53.59% of the company's stock.

Neuronetics Price Performance

NASDAQ STIM traded down $0.22 during trading hours on Friday, reaching $4.43. The company's stock had a trading volume of 817,650 shares, compared to its average volume of 726,572. The firm has a market capitalization of $291.56 million, a price-to-earnings ratio of -3.60 and a beta of 1.92. The company's 50-day moving average is $4.25 and its two-hundred day moving average is $2.85. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.92.

Neuronetics (NASDAQ:STIM - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.08). Neuronetics had a negative net margin of 50.09% and a negative return on equity of 141.24%. The business had revenue of $31.98 million during the quarter, compared to analysts' expectations of $29.07 million. On average, equities analysts predict that Neuronetics, Inc. will post -1.13 EPS for the current year.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group increased their price target on shares of Neuronetics from $5.00 to $8.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th.

Insider Activity

In related news, CEO Keith J. Sullivan sold 40,992 shares of the company's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $3.28, for a total transaction of $134,453.76. Following the completion of the transaction, the chief executive officer now owns 1,283,362 shares in the company, valued at $4,209,427.36. This represents a 3.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Furlong sold 10,845 shares of Neuronetics stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $3.83, for a total value of $41,536.35. Following the completion of the sale, the chief financial officer now owns 471,727 shares in the company, valued at approximately $1,806,714.41. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 100,369 shares of company stock worth $358,929 over the last 90 days. 8.70% of the stock is currently owned by company insiders.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.